Literature DB >> 7684715

Insulinlike growth factor-binding protein modulates the growth response to insulinlike growth factor 1 by human gastric cancer cells.

Y S Guo1, R D Beauchamp, G F Jin, C M Townsend, J C Thompson.   

Abstract

BACKGROUND: This study determined whether the resistance to the mitogenic effect of insulinlike growth factor 1 (IGF-1) in AGS (we found that IGF-1 had almost no effect on the growth of AGS) cells is caused by the absence of IGF-1 receptor on the cells or by the interference of endogenous IGFs and IGF-binding protein (IGFBP).
METHODS: IGF-1 receptors were examined by radioligand binding assay. The protein in conditioned medium and the molecular weight of IGF-1 receptors on AGS cells were determined by affinity cross-linking with 125I-IGF-1 followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Messenger RNAs for IGF-1, IGF-2, and IGFBP-4 were detected by Northern analysis.
RESULTS: AGS cells possessed a single class of high-affinity binding sites for IGF-1 (dissociation constant [Kd], 0.51), with a binding capacity approximately 4 x 10(4) sites per cell. The size of the alpha subunit of IGF-1 receptors on cell membranes was approximately 130 kilodaltons. des (1-3) IGF-1, a truncated IGF-1 with very low affinity to IGFBPs, stimulated AGS cell growth in dose-dependent fashion. The medium conditioned by AGS cells contained IGFBPs of 27-32 and 37-42 kilodaltons. AGS cells expressed messenger (mRNA) RNAs for IGF-2 and IGFBP-4 but not for IGF-1, whereas another gastric carcinoma cell line (SIIA), whose growth is stimulated by IGF-1, expressed mRNA IGF-2 but did not express mRNA for IGF-1 or IGFBP-4:
CONCLUSIONS: The relative absence of growth response of AGS cells to IGF-1 is due to the endogenously produced IGFBPs sequestering IGF-1 and preventing receptor interaction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684715     DOI: 10.1016/0016-5085(93)90634-o

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

1.  Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer.

Authors:  Liwei Wang; Xiaohong Guan; Weida Gong; James Yao; Zhihai Peng; Daoyan Wei; Tsung-Teh Wu; Suyun Huang; Keping Xie
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts.

Authors:  Y Min; Y Adachi; H Yamamoto; A Imsumran; Y Arimura; T Endo; Y Hinoda; C-T Lee; S Nadaf; D P Carbone; K Imai
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

3.  Insulin-like growth factor-I in Helicobacter pylori gastritis and response to eradication using bismuth based triple therapy.

Authors:  A S Taha; G Beastall; R Morton; R H Park; A D Beattie
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

Review 4.  Targeted therapies in gastric cancer treatment: where we are and where we are going.

Authors:  Gianluca Tomasello; Michele Ghidini; Wanda Liguigli; Margherita Ratti; Laura Toppo; Rodolfo Passalacqua
Journal:  Invest New Drugs       Date:  2016-02-12       Impact factor: 3.850

5.  Histamine H2-receptor antagonists stimulate proliferation but not migration of human gastric mucosal cells in vitro.

Authors:  C Ciacci; R Zarrilli; V Ricci; A De Luca; G Mazzacca; C Del Vecchio Blanco; M Romano
Journal:  Dig Dis Sci       Date:  1996-05       Impact factor: 3.199

6.  Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer.

Authors:  Seung Tae Kim; Hye-Lim Jang; Jeeyun Lee; Se Hoon Park; Young Suk Park; Ho Yeong Lim; Min Gew Choi; Jae Moon Bae; Tae Sung Sohn; Jae Hyung Noh; Sung Kim; Kyoung-Mee Kim; Won Ki Kang; Joon Oh Park
Journal:  Transl Oncol       Date:  2015-08       Impact factor: 4.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.